159 related articles for article (PubMed ID: 23826216)
1. Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Kuo LT; Tsai SY; Chang CC; Kuo KT; Huang AP; Tsai JC; Tseng HM; Kuo MF; Tu YK
PLoS One; 2013; 8(6):e67139. PubMed ID: 23826216
[TBL] [Abstract][Full Text] [Related]
2. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
Kuo LT; Kuo KT; Lee MJ; Wei CC; Scaravilli F; Tsai JC; Tseng HM; Kuo MF; Tu YK
Int J Cancer; 2009 Jun; 124(12):2872-9. PubMed ID: 19330828
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
6. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
Mulholland S; Pearson DM; Hamoudi RA; Malley DS; Smith CM; Weaver JM; Jones DT; Kocialkowski S; Bäcklund LM; Collins VP; Ichimura K
Int J Cancer; 2012 Sep; 131(5):1104-13. PubMed ID: 22020830
[TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
11. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
[TBL] [Abstract][Full Text] [Related]
12. Molecular profile of oligodendrogliomas in young patients.
Suri V; Jha P; Agarwal S; Pathak P; Sharma MC; Sharma V; Shukla S; Somasundaram K; Mahapatra AK; Kale SS; Sarkar C
Neuro Oncol; 2011 Oct; 13(10):1099-106. PubMed ID: 21937591
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
14. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
16. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
17. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]